CompletedNCT04592809
Ketamine or midazolam for repeat suicidal behavior in adolescents
About this title
Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
Read the official source — NCT04592809Medication studyAges 13–18United StatesSuicide prevention
Understand this study
Who was this study for?
Listed age limits: 13 years to 18 years.
- Listed locations
- DallasSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: October 3, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 13 Years to 18 Years
- Official registry ID
- NCT04592809
- Official title
Show the full official title
Double-Blind Randomized Controlled Trial of Acute-Course of Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dallas
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Texas Southwestern Medical Center, a university.
Did this study involve medication?
Yes. The study involved medication, including Ketamine Hydrochloride and Midazolam Hydrochloride.
Who was this study for?
Listed age limits: 13 years to 18 years.
